论文部分内容阅读
[目的]探讨血清血管内皮生长因子(VEGF)、癌胚抗原(CEA)、神经元特异性烯醇化酶(NSE)在非小细胞肺癌(NSCLC)诊断中的应用价值,旨在为肺癌的诊治提供理论参考。[方法]采用ELISA方法测定100例NSCLC患者和50例健康查体者血清VEGF、CEA、NSE水平,并分析其与病理分型和临床分期的关系。[结果]肺癌组血清CEA、NSE、VEGF水平均显著高于对照组,相比较差异有统计学意义(P﹤0.05);鳞癌患者血清CEA和NSE水平显著高于腺癌,相比较差异有统计学意义(P﹤0.05);而血清VEGF水平在鳞癌和腺癌患者中差异无统计学意义(P﹥0.05);血清VEGF、CEA、NSE水平随着临床分期的递增而显著上升,其血清水平为Ⅳ期﹥Ⅲ期﹥I～Ⅱ期,3组之间比较差异有统计学意义(P﹤0.05)。[结论]联合检测肺癌患者血清中VEGF、CEA、NSE水平的变化,对NSCLC的早期诊断和鉴别具有重要的临床价值。
[Objective] To investigate the value of serum vascular endothelial growth factor (VEGF), carcinoembryonic antigen (CEA) and neuron specific enolase (NSE) in the diagnosis of non-small cell lung cancer (NSCLC) Provide theoretical reference. [Methods] Serum levels of VEGF, CEA and NSE were measured in 100 NSCLC patients and 50 healthy individuals by ELISA. The relationship between the levels of VEGF, CEA and NSE was analyzed. [Results] The levels of serum CEA, NSE and VEGF in lung cancer group were significantly higher than those in control group (P <0.05). The serum levels of CEA and NSE in patients with squamous cell carcinoma were significantly higher than those in adenocarcinoma (P <0.05). However, there was no significant difference in serum VEGF between squamous cell carcinoma and adenocarcinoma (P> 0.05). Serum levels of VEGF, CEA and NSE increased significantly with the increase of clinical staging Serum levels of stage Ⅳ> stage Ⅲ> stage Ⅰ ~ Ⅱ, the difference between the three groups was statistically significant (P <0.05). [Conclusion] The combined detection of serum VEGF, CEA and NSE levels in patients with lung cancer has important clinical value in the early diagnosis and differential diagnosis of NSCLC.